Redshiftbio

News & Press

February 11, 2025

2025 Structure Lab Grant Program

RedShiftBio Launches Aurora TX for RNA & Protein Analysis

RedShiftBio Welcomes Sebastian Arevalo as New Sales Leader

Tom O’Lenic joins RedShiftBio as Chief Executive Officer

August 30, 2023

RedShift BioAnalytics’ HaLCon Analyzer Awarded Best of Show at the 15th Annual Bioprocessing Summit

August 24, 2023

RedShiftBio Partners with Flownamics for HaLCon Integration

RedShift BioAnalytics Launches Aurora MMS Platform

RedShiftBio Launches HaLCon™ for Protein Analysis

RedShift BioAnalytics Announces Acquisition of Novel Liquid Chromatography Protein Analyzer Technology

RedShiftBio Launches Apollo for Biomolecular Analysis

RedShift BioAnalytics announces partnership with DKSH, expanding the MMS market in Asia Pacific

November 16, 2021

SCIEX & RedShiftBio Expand MMS for Biotherapeutic Analysis

October 18, 2021

RedShift BioAnalytics Closes $20M Series E Funding Led by Illumina Ventures

October 6, 2021

New StructIR Scientific Services Lab and Grant Program available from RedShiftBio

September 7, 2021

RedShift BioAnalytics Appoints Amol Chaubal to Board of Directors

February 18, 2021

RedShift BioAnalytics Announces 500% Sales Growth in 2020 and Closing of Additional Financing

October 15, 2020

RedShiftBio Expands Team to Support Demand for AQS³pro

October 5, 2020

Peer-reviewed study demonstrates higher sensitivity, repeatability, and utility relative to conventional FTIR

September 9, 2020

RedShiftBio Appoints Spinco Biotech as Exclusive Indian Distributor

RedShiftBio Appoints Primetech as Exclusive Distributor in Japan

RedShiftBio Appoints Topbiox as Exclusive Distributor in China

Pressure BioSciences & RedShiftBio: Potential of Combining Technologies

December 2, 2019

The AQS³pro - A Hit For The Second Year Running at PEGS Europe

November 21, 2019

Accelerating Novel And Complex Modules Towards CMC Success

November 20, 2019

MIBio 2019: A Huge Success for RedShiftBio

October 21, 2019

Monitoring Biotherapeutic Protein Aggregation - American DDF Summit

August 23, 2019

Protein Aggregation Monitoring: Bioprocessing Summit 2019

August 20, 2019

RedShiftBio at The Colorado Protein Stability Conference 2019

RedShiftBio’s AQS³pro Changes the Game in the Detection and Treatment of Alzheimer’s

Scientists See Change in Higher Order Structure with MMS at HOS 2019

Inspiring innovative biotherapeutic drug development at PEGS 2019

RedShiftBio Shipping AQS³pro as Industry Endorsements Expand

Higher Order Structure: Hot Topic at Biotherapeutics Analytical Summit

February 15, 2019

RedShiftBio at Biotherapeutics & Vaccines Development (GRC)

February 15, 2019

RedShiftBio Shines at PepTalk 2019

February 15, 2019

AQS³®pro offers breakthrough in bioanalytical technology at WCBP 2019

January 31, 2019

RedShiftBio’s AQS³pro: Finalist in The Prism Awards 2019

January 28, 2019

Photonics Media publishes article on Technological Synergies Move Spectroscopy Out of the Lab

December 14, 2018

RedShiftBio’s AQS³pro Wins a ‘The Analytical Scientist Innovation Award’ (TASIA) 2018

October 31, 2018

American Pharmaceutical Review publishes article on MMS by Karan K. Shah of ImmunoGen, Inc.

October 5, 2018

Advancing Protein Characterization: Overcoming Challenges with Innovative Techniques

August 26, 2018

Immunogen presents MMS data in talk at Bioprocessing Summit 2018

August 17, 2018

RedShiftBio Strengthens Focus on Applications with New Hire

August 17, 2018

Workshop on Protein Aggregation and Immunogenicity 2018

Spectroscopy North America publishes paper on MMS from RedShiftBio

RedShiftBio Expands Team for AQS³pro Protein Analysis Launch

RedShiftBio Stole the Show at PEGS 2018 with the Launch of AQS³pro

Instrument Business Outlook interviews RedShiftBio CCO on the AQS³pro

Spectroscopy Europe highlights the launch of the AQS³pro

RedShiftBio Launches AQS³pro Protein Characterization System

RedShiftBio presents MMS data at HOS 2018

RedShiftBio at Biotherapeutics Analytical Summit 2018

RedShiftBio Announces Collaboration Trial Completion

MMS technology for protein characterization at Biophysical Society 2018

February 28, 2018

RedShiftBio showcases new analytical techniques at PepTalk 2018

Jeffrey Zonderman Joins RedShiftBio as its Chief Commercial Officer

RedShiftBio Inc. Completes $11.0 million Series C Financing

Unfortunately, we couldn't find any News Articles matching your criteria.

Request a Demo Today!

RedShiftBio AQS3 Product Detail